Physician profile
Armando A Sanchez
NPI 1881692937
$611.46
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $108 · 2021: $145 · 2022: $36.80.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $152.84 | 2019-2020 | |
| Amgen INC. | $148.56 | 2019-2021 | |
| Novo Nordisk INC | $96.85 | 2019-2021 | |
| Glaxosmithkline, LLC. | $77.91 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $53.28 | 2020-2021 | |
| Abbvie INC. | $39.95 | 2021 | |
| Amarin Pharma, INC. | $16.11 | 2019 | |
| Gilead Sciences, INC. | $14.60 | 2019 | |
| Merck Sharp & Dohme LLC | $11.36 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Armando Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.